-
公开(公告)号:US10435399B2
公开(公告)日:2019-10-08
申请号:US16049359
申请日:2018-07-30
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: Masahiro Ito , Hideyuki Sugiyama , Osamu Kubo , Fumiaki Kikuchi , Takeshi Yasui , Keiko Kakegawa , Zenichi Ikeda , Tohru Miyazaki , Yasuyoshi Arikawa , Tomohiro Okawa , Jinichi Yonemori , Akinori Toita , Takuto Kojima , Yasutomi Asano , Ayumu Sato , Hironobu Maezaki , Shinobu Sasaki , Hironori Kokubo , Misaki Homma , Minoru Sasaki , Yasuhiro Imaeda
IPC: C07D413/14 , C07D413/04 , C07D417/14 , C07D487/04 , A61P25/28 , C07D471/04
Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.